Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group
Nicolaus Kröger, Andrea Bacigalupo, Tiziano Barbui, et al.
The Lancet Haematology (2023) Vol. 11, Iss. 1, pp. e62-e74
Closed Access | Times Cited: 44

Showing 26-50 of 44 citing articles:

Anemia in Myelofibrosis: A Focus on Proactive Management and the Role of Momelotinib
Haifa Kathrin Al‐Ali, Andrew Kuykendall, Catherine Ellis, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 4064-4064
Open Access | Times Cited: 1
Risk models in myelofibrosis—the past, present, and future
Ayalew Tefferi, Alessandro M. Vannucchi
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 519-522
Closed Access
Post-transplant cyclophosphamide: A double-edged sword?
Alessandro Busca
Leukemia Research (2024) Vol. 143, pp. 107543-107543
Closed Access
Myelofibrosis and allogeneic transplantation: critical points and challenges
Paola Ranalli, Annalisa Natale, Francesco Guardalupi, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
The Gordian knot: ruxolitinib or transplants for high-risk myelofibrosis
Robert Peter Gale, Giovanni Barosi
Haematologica (2024)
Open Access
Applications of artificial intelligence to myeloproliferative neoplasms: a narrative review
Andrew Srisuwananukorn, Jordan E. Krull, Qin Ma, et al.
Expert Review of Hematology (2024) Vol. 17, Iss. 10, pp. 669-677
Open Access
Prognostic and Predictive Models in Myelofibrosis
Barbara Mora, Cristina Bucelli, Daniele Cattaneo, et al.
Current Hematologic Malignancy Reports (2024) Vol. 19, Iss. 5, pp. 223-235
Open Access
SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis
Michael J. Hochman, Colin A. Vale, Anthony M. Hunter
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access
JAK Inhibitors for Myelofibrosis: Strengths and Limitations
Kyaw Htin Thaw, Claire Harrison, Priya Sriskandarajah
Current Hematologic Malignancy Reports (2024) Vol. 19, Iss. 6, pp. 264-275
Open Access
Spatial-transcriptomic profiling: a new lens for understanding myelofibrosis pathophysiology
Edoardo Peroni, Elisabetta Calistri, Rosario Amato, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access
What are the therapeutic options for previously treated myelofibrosis?
C. Petit, Hugues de Lavallade, Claire Harrison
Expert Review of Hematology (2024), pp. 1-12
Closed Access
Fedratinib as an alternative to splenectomy for refractory splenomegaly prior to transplant for myelofibrosis
James T. England, Taylor Nye, Verna Cheung, et al.
Bone Marrow Transplantation (2024)
Closed Access
When and how to transplant in myelofibrosis – recent trends
Naman Sharma, Giuseppe Gaetano Loscocco, Naseema Gangat, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-19
Closed Access
Molecular profiling in MPN: who should have it and why?
Ashlyn Chee, Adam J. Mead
Hematology (2024) Vol. 2024, Iss. 1, pp. 524-534
Closed Access
Importance of allogeneic stem cell transplantation in myelofibrosis
Klaus Hirschbühl, Christoph Schmid
memo - Magazine of European Medical Oncology (2024) Vol. 17, Iss. 3, pp. 215-219
Open Access
A Comparative Analysis of Low Dose Grafalon ® Versus Thymoglobuline ® as Serotherapy in Hematopoietic Stem Cell Transplant in Pediatric and Young Adult Population
Garima Nirmal, Gaurav Kharya, Ravi Shankar, et al.
Pediatric Hematology and Oncology (2024), pp. 1-15
Closed Access
Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations
Alberto Carturan, Sonia Morè, Antonella Poloni, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 4113-4113
Open Access
Peri‐Transplant Management of JAK Inhibitor Therapy in Myelofibrosis
Ayalew Tefferi, Vincent T. Ho
American Journal of Hematology (2024)
Open Access
Treatment of Philadelphia Chromosome-negative Myeloproliferative Neoplasms in 2024: A Concise Review
Akhil Rajendra, Dawn Maze
Canadian Hematology Today (2024)
Closed Access
Previous Page - Page 2

Scroll to top